Posted by Michael Wonder on 05 Feb 2018
Cancer research funding has an inherent bias that often excludes rare cancers, expert says
3 February 2018 - The biggest investor in cancer research in Australia needs to address an "inherent bias" in how it decides which projects get funding, an oncologist specialising in rare tumours says.
The National Health and Medical Research Council (NHMRC) has previously been criticised for appearing to favour research into common cancers, which have comparatively high survival rates and attract more financial support from philanthropic groups.
Last year, a cross-party Senate committee recommended the NHMRC make rare cancer research an official priority, but the Federal Government agency is yet to decide on that.
